No Data
No Data
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $60
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $50 to $100
Citizens Capital Markets Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $87
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $80 to $93